Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial - Potential Best-in-Class Non-Hormonal Treatment For Vasomotor Symptoms
Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.
